Alnylam Pharmaceuticals
ALNY
#659
Rank
C$52.53 B
Marketcap
C$393.48
Share price
-0.25%
Change (1 day)
-3.40%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): C$5.27

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is C$5.21. In 2025 the company made an earnings per share (EPS) of C$2.47.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)C$5.27113.04%
2025C$2.47
2023C-$4.85-62%
2022C-$12.7729.03%
2021C-$9.90-3.36%
2020C-$10.24-8.48%
2019C-$11.197.67%
2018C-$10.3939.74%
2017C-$7.4412.94%
2016C-$6.5838.84%
2015C-$4.74-32.88%
2014C-$7.06259.44%
2013C-$1.97-31.25%
2012C-$2.86

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
C$9.65 85.22%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
C$3.52-32.46%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
C$58.46 1,022.16%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
C-$11.44-319.53%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
C-$1.00-119.26%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
C-$0.33-106.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
C$1.88-63.85%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
C$0.48-90.77%๐Ÿ‡บ๐Ÿ‡ธ USA